Losartan is named as an intervention in 10 current clinical trials in our Brazil, Germany, Austria, Italy, Denmark, Norway, Turkey, Mexico, South Korea and Israel registers. 5 are recruiting patients now. The most common phase is Not applicable. The sponsor with the most trials is Valentina Puentmann (1). The most-studied condition is COVID-19 Associated Cardiac Involvement. The EU clinical trials register (CTIS) separately lists 2 authorised or ongoing trials.
Losartan was first approved in the US on 14 Apr 1995. It is approved in 2 of the 3 regulators tracked here.
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Authorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Losartan. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
The GranStone Trial - Prevention of Kidney Stones due to Paraffin Oil Induced Granuloma
2026-525608-85-00 · CTIS ↗ · Musculoskeletal Diseases
|
Phase 3 | Authorised | Region Hovedstaden | Denmark |
|
Withdrawal of neurohormonal therapy in patients with non-ischemic cardiomyopathy, no late gadolinium enhancement, and negative genetic testing, who have exhibited super-response to cardiac resynchronization therapy. DRUGLESS-CRT clinical trial.
2025-521780-12-00 · CTIS ↗ · Cardiovascular Diseases
|
Phase 3 | Ongoing | Andrea Di Marco | Spain |
The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
21 single-substance products containing Losartan on the HPRA medicines list.
No entry for Losartan in the EMA, FDA or German BfArM shortage lists we track.
| Condition (as registered) | Trials |
|---|---|
| COVID-19 Associated Cardiac Involvement | 1 |
| Remodeling, Left Ventricle | 1 |
| Remodeling, Vascular | 1 |
| Left Ventricular Dysfunction | 1 |
| Glomerulonephritis | 1 |
| Immunoglobulin A Nephropathy | 1 |
| Paraffinoma | 1 |
| Granuloma, Foreign-Body | 1 |
| Obesity, Morbid | 1 |
| Adhesive Capsulitis of Shoulder | 1 |
| Obesity & Overweight | 1 |
| Bariatric Surgery | 1 |
| Pharmacokinetics After Oral Intake | 1 |
| Drug Absorption | 1 |
| Heart Valve Diseases | 1 |
| Left Ventricle Remodeling | 1 |
| Aortic Regurgitation Disease | 1 |
| Heart Failure Congestive | 1 |
| Corneal Scarring Fibrosis | 1 |
| Hypertension | 1 |
| Pancreatic Cancer | 1 |
| Lead sponsor | Trials |
|---|---|
| Valentina Puentmann | 1 |
| Fondazione Schena | 1 |
| Martin Blomberg Jensen | 1 |
| Norwegian University of Science and Technology | 1 |
| Istanbul University | 1 |
| Hospital das Clínicas de Ribeirão Preto | 1 |
| Vitor Emer Egypto Rosa | 1 |
| Universidad Autonoma de Nuevo Leon | 1 |
| Huons Co., Ltd | 1 |
| Massachusetts General Hospital | 1 |
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
10 current trials in our Brazil, Germany, Austria, Italy, Denmark, Norway, Turkey, Mexico, South Korea and Israel registers name Losartan as a drug or biological intervention, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.
Yes. 5 of the 10 trials are recruiting: 1 with sites in Brazil, 1 with sites in Italy, 1 with sites in Norway, 1 with sites in Turkey and 1 with sites in Mexico. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Valentina Puentmann (1), Fondazione Schena (1), Martin Blomberg Jensen (1) and Norwegian University of Science and Technology (1), among 10 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Yes. The HPRA medicines list includes 21 single-substance products containing Losartan, for example Cozaar 100 mg Film-coated Tablets (Organon Pharma (Ireland) Limited). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Not in the lists we track: Losartan has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Losartan works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Losartan works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Losartan (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 27 Sep 2026.